Aurobindo Acquires Four Biosimilars, Including Avastin Biosimilar Molecule
By

By
Aurobindo Pharma, a Hyderabad, India-headquartered generics and active pharmaceutical ingredients manufacturer, has acquired four cell-culture-derived biosimilar candidates from TL Biopharmaceutical AG, based in Switzerland. Three of the four candidates are…

Seattle Genetics in $2-Billion ADC Oncology Deal
By

By
Seattle Genetics, a Bothell, Washington-headquartered biotechnology company, has entered into a development and license agreement with Immunomedics, a Morris Plains, New Jersey-based biopharmaceutical company, under which Seattle Genetics would receive…

Neurocrine Nabs Parkinson’s Disease Drug in $145-Million Deal
By

By
Neurocrine Biosciences, a San Diego-based biopharmaceutical company focused on neurological and endocrine diseases, has entered into an exclusive licensing agreement with Bial, a Trofa, Portugal-headquartered pharmaceutical company, to develop and…

Amgen and Lilly Lead Drug Approval News
By

By
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Amgen and Lilly. Editor’s Note: This article is updated on a continuous basis for news announced…

Daiichi Sankyo to Close Research Subsidiary
By

By
Daiichi Sankyo Group has decided to close its Japanese research subsidiary, Asubio Pharma, based in Kobe, Japan, by the end of March 2018 as part of a reorganization of the…

Allergan to Acquire Medical Technology Company in $2.5-Billion Deal
By

By
Allergan has agreed to acquire Zeltiq Aesthetics, a Pleasanton, California-headquartered medical technology company that specializes in a proprietary controlled-cooling technology platform for body sculpting, for $56.50 per share, or $2.475…

Janssen Out-Licenses Irritable-Bowel-Disease Drug
By

By
Janssen Pharmaceutica, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has entered into an exclusive agreement with Akebia Therapeutics, a biopharmaceutical company headquartered in Cambridge, Massachusetts focused on…

Astellas Makes Senior Appointments: Forms Division for CMO Management
By

By
Astellas Pharma has announced changes in its top management structure, effective on April 1, 2017 and has formed a division, Pharmaceutical Technology, to manage its contract manufacturing organization (CMO) relationships…

Pfizer to Close Australian Neulasta Biosimilar Plant by 2021
By

By
Pfizer has announced that it will close its Adelaide, Australia manufacturing plant, which produces the active ingredient in Pfizer’s biosimilar candidate to Amgen’s anti-cancer drug, Neulasta (pelfilgrastim), by 2021. Neulasta,…

Incyte, Agenus Amend Immuno-Oncology Deal
By

By
Incyte, a Wilmington, Delaware-based biopharmaceutical company, and Agenus, a Lexington, Massachusetts-based clinical-stage immuno-oncology company, have amended a license, development, and commercialization agreement for antibody programs that the companies originally entered…